[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"positron-emission-tomography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:positron-emission-tomography":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,40,69,106,137,165,182,223,245,267,297,324,345,360,382,401,422,437,470,506,537,558],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100550963","early-phase-1-neuroflipp-parametric-pet-of-neuroinflammation-in-fatty-liver-disease-100550963",false,"NCT06453915","NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease","NeuroFLiPP - Parametric PET of Neuroinflammation in Fatty Liver Disease","Inclusion Criteria:\n\n* Participants \\>=18 years age\n* Participants who have or have planned a liver biopsy as:\n\n  * standard of care for fatty liver disease with risk factors for metabolic dysfunction-associated steatohepatitis (MASH), or\n  * as part of another Clinical Trials study for MASH, or\n  * standard of care prior to undergoing bariatric surgery\n  * Liver biopsy needs to be within 6 months of planned study-related imaging\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease other than non-alcoholic fatty liver disease.\n* Uncontrolled claustrophobia\n* Body weight \\>225 kg due to limitations of the scanner bed\n* Pregnant or breast-feeding (due to risks of ionizing radiation; urine pregnancy test will be administered prior to start of each PET\u002FCT session for all participants between 18 to 60 years old who are able to get pregnant, unless documented hysterectomy is available)\n* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n* Prisoners\n* Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.\n* Pre-existing neurodegenerative disorders and dementia\n* Significant history of major skull concussion or repetitive head trauma\n* Currently on anticoagulant therapy\n* Metal implants (e.g., pacemaker) or claustrophobia that would preclude MRI scans","ALL","18 Years",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one-third of the U.S. population, might influence ADRD through the liver-brain axis. MASLD shares risk factors with Alzheimer's, such as diabetes and hypertension, and studies have linked MASLD to increased risks of cognitive decline and ADRD. Mouse-model studies suggest that chronic liver inflammation in MASLD can induce neuroinflammation and accelerate Alzheimer's pathology, highlighting the importance of studying the liver-brain connection to identify new therapeutic targets for ADRD.\n\nThe goal of this research is to develop a practical PET imaging method using 18F-FDG to simultaneously assess liver and brain inflammation in patients with MASLD-related ADRD. This approach leverages dynamic FDG-PET scanning and advanced tracer kinetic modeling to quantify glucose transport, overcoming limitations of traditional imaging methods that cannot noninvasively assess chronic liver inflammation. The new method aims to enable comprehensive imaging of liver-brain inflammation crosstalk, validated against the 18F-DPA-714 radiotracer. Success in this project could provide a valuable imaging tool for linking liver inflammation with neuroinflammation and cognitive decline, advancing clinical research and potentially uncovering new pathways for ADRD treatment",[26],"Positron Emission Tomography","RECRUITING","2026-06-16",{"date":30,"type":31},"2026-06-18","ACTUAL",{"date":33,"type":31},"2025-04-30",{"date":35,"type":20},"2027-07",{"name":37,"class":38},"University of California, Davis","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":47,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100638493","programmed-cell-death-ligand-1-petct-in-various-pd-l1-related-disease-patients-100638493","NCT07618936","Programmed Cell Death Ligand 1 PET\u002FCT in Various PD-L1-Related Disease Patients","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PD-L1 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","80 Years",{"count":48,"type":20},500,"7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-PD-L1 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various PD-L1-related disease patients",[53,54,55,26],"PD-L1 Gene Mutation","PD-L1 Gene Amplification","PD-L1-related Disease",[57,58,59],"PET\u002FCT","PD-L1","DMP10","2026-05-24",{"date":62,"type":31},"2026-06-01",{"date":62,"type":20},{"date":65,"type":20},"2031-06-01",{"name":67,"class":38},"Tianjin Medical University",2,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":92,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":39},"100564857","early-phase-1-imagemhtt-009--fih-evaluation-of-novel-mutant-huntingtin-pet-radioligand-11cchdi-00491009-100564857","NCT06634628","iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009","First in Human Adaptive Study to Investigate the Kinetic Properties of the Novel PET Radioligand [11C]CHDI-00491009 and Its Suitability for Quantification of Aggregated Mutant Huntingtin in the Brains of People With Huntington's Disease","iMagemHTT-009","Inclusion Criteria:\n\nPwHD HD-ISS Stages 2 and 3 and HC participants who:\n\n1. Are female or male adults, age 18-64 years old, inclusive.\n2. Have body mass index (BMI) between 19 and 35, inclusive.\n3. Have capacity to give full informed consent in writing and have read and signed the informed consent form (ICF).\n4. Are able to comply with study procedures, including fasting and blood sampling.\n5. Are able and willing to travel to the imaging center in Leuven, Belgium.\n6. Are willing to comply with the use of adequate contraceptive measures.\n\n   HD-ISS Stage 2 participants who:\n7. Have a huntingtin gene CAG expansion between 40 and 50, inclusive; and\n8. Are classified within HD-ISS Stage 2 per the HD-ISS criteria using HD-ISS Modified Stage calculator.\n9. Have a PIN score of 0.47 to 1.84 \\[prognostic index normed for HD (PIN) where PIN = (PIHD - 883)\u002F1044 where PIHD = 51 x TMS + (-34) x SDMT + 7 x Age x (CAG - 34) (TMS is the UHDRS Total Motor Score, and SDMT is the UHDRS Symbol Digit Modalities Test)\\].\n\nHD-ISS Stage 2 participants who:\n\n7\\. Have a huntingtin gene CAG expansion between 40 and 50, inclusive; and 8. Are classified within HD-ISS Stage 2 per the HD-ISS criteria using HD-ISS Modified Stage calculator.\n\n9\\. Have a PIN score of 0.47 to 1.84 \\[prognostic index normed for HD (PIN) where PIN = (PIHD - 883)\u002F1044 where PIHD = 51 x TMS + (-34) x SDMT + 7 x Age x (CAG - 34) (TMS is the UHDRS Total Motor Score, and SDMT is the UHDRS Symbol Digit Modalities Test)\\].\n\nHC participants who:\n\n13\\. Have no known family history of HD; or 14. Have a known family history of HD and have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG \\\u003C 36).\n\n15\\. Age match (+\u002F- 5 years) and biological sex match to each HD participant in Cohort 2 and Cohort 3 (except for Cohort 1, no matching).\n\nExclusion Criteria:\n\nPwHD HD-ISS Stages 2 and 3 and HC participants who:\n\n1. Are currently participating in, or are less than 30 days after completing participation in, other therapeutic or imaging studies.\n2. Have previously participated in a PET imaging study in the past 12 months that, cumulatively with the current study, will exceed annual regulatory limits for radiation exposure.\n3. Have any disease, condition, or concomitant medication that significantly compromises the function of the body systems and that, in the opinion of the Investigator, might interfere with the conduct of the study or its interpretation.\n4. Are pregnant and breastfeeding females.\n5. Have concomitant use of antiplatelet or anticoagulant therapy (inclusive of acetylsalicylic acid).\n6. Have a bleeding disorder.\n7. Have a needle phobia.\n8. Have any metal objects present in the body that are incompatible with MRI.\n9. Have metal objects present in the body that are compatible with MRI and are located in the head or neck.\n10. Have any clinically significant results on safety laboratory tests that, in the opinion of the Investigator, would either put the participant at risk or interfere with the conduct of the study or interpretation of data. These tests include, but are not limited to:\n\n    * a. positive results for HBsAg, HepC, HIV-1 or HIV-2 (will also be reported as required by local\u002Fnational regulations),\n    * b. clinically significant, abnormal results for safety laboratory tests.\n\n    PwHD participants who:\n11. If they are using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to participation.\n\n    HC participants who:\n12. Have a family history of HD and have not been tested for the huntingtin gene (CAG) expansion.",true,"64 Years",{"count":80,"type":20},27,[23],"This is a FIH (first-in-human) study to evaluate the clinical utility of the radioligand \\[11C\\]CHDI-00491009 as a PET tracer that binds specifically to mutant huntingtin (mHTT) aggregates in Huntington's disease (HD).\n\nThe study is divided into three cohorts defined by the Huntington's Disease Integrated Staging System (HD-ISS): Cohort 1 - initial tracer validation (3 healthy controls (HCs)); Cohort 2 - target validation and test-retest variability (6 HD-ISS Stage 3 participants and 6 age and biological sex-matched HCs); Cohort 3 - target sensitivity (6 HD-ISS Stage 2 participants and 6 age and biological sex-matched HCs). An interim analysis (IA) will be conducted after the completion of each cohort, followed by a final analysis for the study.\n\nIn addition to imaging, exploratory biomarkers, including somatic instability index, soluble mHTT and total huntingtin (HTT), will be assessed. All participants with HD (PwHD) will have an additional blood sample drawn at the screening visit to assess the somatic instability index and will also be invited to provide an optional cerebrospinal fluid (CSF) sample for measurement of soluble mHTT and total HTT.",[84,85,86,26,87,88,89,90,91],"Huntington Disease","HD","PET Tracer","Radioligand","Imaging","mHTT","Huntington's","Huntington's Disease",[93,84,85,86,26,94,95,89,96,91],"iMagemHTT","radioligand","imaging","huntingtin","2026-03-12",{"date":99,"type":31},"2026-03-13",{"date":101,"type":31},"2026-02-24",{"date":103,"type":20},"2028-03",{"name":105,"class":38},"CHDI Foundation, Inc.",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":113,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100437962","metastasis-directed-stereotactic-body-radiotherapy-for-oligo-metastatic-hormone-sensitive-prostate-cancer-100437962","NCT04983095","Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer","METRO","Inclusion Criteria:\n\n1. Histologically confirmed prostate cancer (ICD-O-3 C61)\n2. WHO\u002FECOG performance status 0-1\n3. 1-3 skeletal or extra pelvic lymph node metastases detected by PSMA-PET\u002FCT in de novo prostate cancer or PSA-relapse after definitive RT or prostatectomy\n4. Willing and able to provide informed consent-\n\nExclusion Criteria:\n\n1. Castration resistant prostate cancer (progression with castrate levels of testosterone)\n2. Any treatment known to affect PSA (including ADT) for prostate cancer within 6 months (exception: ADT started due to oligometastatic disease within 2 weeks of study entry)\n3. Patient eligible for other treatment (e.g., early docetaxel) than standard treatment described in the protocol as judged by treating physician\n4. Life expectancy \\\u003C3 years by any reason, including concomitant or previous malignancies\n5. Previous radiotherapy or surgery that may interfere with the planned treatment (including intra-prostatic recurrence if previous RT to the prostate)\n6. \\> 3 PSMA-PET\u002FCT positive target lesions (excluding the prostate and regional lymph node metastasis in de novo patients or prostate bed and or regional lymph node metastasis in recurrent patients)\n7. PSMA-PET verified metastases other than skeletal or lymph nodes\n8. Metastases in base of scull and\u002For calotte\n9. Any target lesions not treatable with image guided RT (IGRT) due to overlap with previous RT fields or exceeded dose constraint to OAR(s) as specified in study protocol","MALE",{"count":115,"type":20},118,[117],"NA","The study is an open label, multi-centre, randomized phase III study. The patients will be randomised in a 1:1 ratio to treatment consisting of\n\n* Arm A: MD-SBRT in addition to standard treatment\n* Arm B: Standard treatment\n\nStudy population: Patients with hormone sensitive prostate cancer (HSPC) with oligometastatic disease detected by PSMA-PET\u002FDT. This includes patients with de novo oligometastatic HSPC and recurrent HSPC after primary RT or prostatectomy.\n\nPrimary endpoint: Failure free survival\n\nSecondary endpoints:\n\n* Predictive value of investigated biomarkers in blood and imaging\n* Acute and late toxicity after MD-SBRT\n* PROM at 3 months, 1, 3 and 5 years\n* Castration resistant prostate cancer, CRPC\n* Overall survival\n* Differences in outcome between patients by strata\n\nStratification: To avoid imbalance between treatment arms the minimisation method will be used to achieve balance between de novo oligo-metastatic and oligo-recurrent patients, as well as treatment site.\n\nSafety evaluation: Adverse events and side effects graded according to CTCAE v5.0 will be collected every 6th month. Serious Adverse Events are to be reported within 24 hours throughout the study duration.\n\nStatistical methods: Survival endpoints will be calculated using the Kaplan-Meier method with differences compared using the stratified log-rank test. Randomization time is set as baseline time. Pre-planned subgroup analysis will occur based on pre-specified stratification variables. A Cox multivariable regression model will be used to determine factors predictive of survival. Safety analysis will be performed with Mann-Whitney U-test or Fishers exact test.\n\nCriteria for evaluation: Per protocol (patients that have started study treatment) and Intention to treat (all included patients).\n\nPlanned sample size: 118 patients\n\nAnalysis plan:\n\nThe primary end point will be analysed after pre-specified number of events have occurred. All patients randomised to SBRT will be followed minimum 60 months for toxicity. Safety analysis of acute toxicity will take place after median follow up of 6 months. Safety analysis of late toxicity will be analysed after study closure.\n\nDuration of the study:\n\nThree to five years inclusion. 72 months of follow-up after randomization of the last patient.",[120,121,122],"Prostate Cancer Metastatic","Radiation Therapy","Positron-Emission Tomography",[124,125,126],"Oligometastatic Prostate Cancer","Hormone Sensitive","Stereotactic Body Radiotherapy","2026-02-11",{"date":129,"type":31},"2026-02-17",{"date":131,"type":31},"2021-10-27",{"date":133,"type":20},"2033-12",{"name":135,"class":38},"Karin Soderkvist",7,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":39},"100478957","serotonin-release-in-premotor-and-motor-pd-100478957","NCT05516732","Serotonin Release in Premotor and Motor PD","Evaluation of Serotonergic Neurotransmission in Premotor and Motor Parkinson's Disease.","FOX3","Inclusion criteria-\n\n* Subjects must understand the nature of the study and must provide signed and dated written HRA-approved informed consent in accordance with local regulations before any protocol-specific screening procedures are performed;\n* Males and females, age 25-85 years, inclusive;\n* Women of child-bearing potential must use protocol-defined contraceptive measures and must have a negative β-hCG test at screening. For sexually active subjects (except females of non-childbearing potential-e.g., at least 2 years postmenopausal or surgically sterile), condoms should be used in addition to other birth control methods for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. These patients must be willing to remain on their current form of contraception for the duration of the study. All male subjects must agree to refrain from donating sperm for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. Sexually active male subjects must agree to use condoms to protect their partners from becoming pregnant for the duration of the study and for 3 months after the last administration of PET or SPECT ligands (i.e. for 15 consecutive months following baseline PET and SPECT scans); agree to ensure that they and their partners are routinely using a medically approved contraceptive method. It is important that male subjects not impregnate others for the duration of the study and for 3 months after the last administration of PET or SPECT ligands;\n* Able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures;\n* Adequate visual and auditory acuity to complete the psychological testing;\n* In the opinion of the investigator, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.\n\nExclusion criteria -\n\n* Subjects lacking capacity according to investigator judgement;\n* Subjects taking serotonin acting drugs such as antidepressants (i.e. tricyclic or selective serotonin reuptake inhibitors etc.);\n* Pregnancy or breastfeeding or intent to become pregnant in the next 18 months;\n* Subjects with current or a recent history of drug or alcohol abuse\u002Fdependence;\n* Subjects who have other neurological disorders and known intracranial co-morbidities such as stroke, hemorrhage, space-occupying lesions;\n* Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgment of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results;\n* History of suicidal behaviour or active suicidal ideation;\n* Within 1 year prior to screen or between screen and baseline (Day -1), any of the following: myocardial infarction; hospitalization for congestive heart failure; hospitalization for, or symptoms of, unstable angina; or syncope not related to PD;\n* History or presence of renal disease or impaired renal function;\n* Clinically important infection (e.g., chronic, persistent, or acute infection) within 30 days prior to screen or between screen and baseline (Day -1);\n* History of cancer within the last 5 years, with the exception of nonmetastatic basal cell carcinoma of the skin;\n* Clinically significant blood clotting or bleeding disorder, including clinically significant abnormal findings in laboratory assessments of coagulation or hematology;\n* Use of antipsychotic medication within 3 months prior to screen or between screen and baseline (Day -1);\n* Use of any anticoagulant within 30 days prior to baseline and follow-up PET scans;\n* Use of any oral corticosteroid within 30 days prior to baseline and follow-up PET scans;\n* Use of metoclopramide within 30 days prior to baseline and follow-up (Day -1);\n* Use of any thyroid medication within 30 days prior to baseline and follow-up (Day -1);\n* Regular use (e.g., taken \\> 3 days\u002Fweek) of narcotic pain medications within 30 days prior to baseline and follow-up (Day -1);\n* Presence of any of the following MRI contraindications: pacemaker; cardiac defibrillator; spinal cord or vagus nerve stimulator; aneurysm clip; artificial heart valve; recent coronary or carotid stent; ear implant; CSF shunt; other implanted medical device (e.g., Swan-Ganz catheter, insulin pump); or metal fragments or foreign objects in the eyes, skin, or body;\n* Negative modified Allen test in both hands, unless the brachial artery is used for arterial cannulation;\n* Claustrophobia or history of back pain that makes prolonged laying on the PET or MRI scanner intolerable;\n* History of severe skin allergy;\n* Patients who had previous surgery for PD (including but not limited to deep brain stimulation \\[DBS\\] or cell transplantation);\n* Patients who are treated with duodopa or apomorphine;\n* Initiation or change in pharmacologic therapy for symptoms of PD within 30 days prior to screen or between screen and baseline and follow-up (Day -1).\n* GDS score greater than or equal to 10 (GDS score of 5 - 9 requires Investigator discretion to enter study).\n* STAI Form Y-1 greater than or equal to 54 requires Investigator discretion to enter study.","25 Years","85 Years",{"count":148,"type":20},42,"In this study, the investigators aim to provide a deeper understanding of Parkinson's disease and find a biomarker of Parkinson's disease. This is done using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The findings will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of Parkinson's disease symptoms",[151,152,153,154,155,26],"Parkinson Disease","Parkinson's","Parkinson's Disease","Neurodegenerative Diseases","Neurodegeneration","2025-10-01",{"date":158,"type":31},"2025-10-07",{"date":160,"type":31},"2022-07-01",{"date":162,"type":20},"2026-06-30",{"name":164,"class":38},"University of Exeter",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":77,"sex":16,"minAge":145,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":181,"locationsCount":39},"100478956","longitudinal-investigation-of-i2bs-in-pd-100478956","NCT05516719","Longitudinal Investigation of I2BS in PD","Longitudinal Investigation of Imidazoline-2 Binding Site as a Novel Marker of Disease Progression in Parkinson's Disease: An [11C]BU99008 PET Study","FOX_2","Inclusion criteria\n\n* All subjects must be judged by the investigator able to understand the nature, design, and procedures of the study and must be able to provide a signed and dated informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations.\n* All subjects must be willing and able to comply with scheduled visits, required study procedures and laboratory tests.\n* All subjects must be able to travel to the research sites for the study procedures.\n* Age 25 years or older.\n* For female subjects: They must be either of non-childbearing potential (either surgically sterile or post- menopausal - defined as 12 months of spontaneous amenorrhea), or, if of childbearing potential, subjects must demonstrate to be non-pregnant (as demonstrated by negative urine β-HCG test at screening), non-breastfeeding.\n* All subjects must comply with highly effective contraceptive measures. A highly effective contraceptive measure is defined as a measure that can achieve a failure rate of less than 1% per year when used consistently and correctly. These methods are listed in more detail below:\n\nOral, intravaginal, or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation;\n\nOral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation:\n\nIntrauterine device (IUD)\n\nIntrauterine hormone-releasing system (IUS)\n\nBilateral tubal occlusion\n\nVasectomised partner\n\nSexual abstinence\n\n* For sexually active male subjects, they must agree to use condoms to protect their partners from becoming pregnant for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. They must also agree to ensure that they and their partners are routinely using a medically approved contraceptive method. It is important that male subjects not impregnate others for the duration of the study and for 3 months after the last administration of PET or SPECT ligands.\n* All subjects must have adequate visual and auditory acuity according to investigator's judgement to complete the psychological testing.\n* All subjects must have no use of medications with known interaction with I2BS (e.g. idaxozan, efaroxan, yohimbine, atomoxetine, atipamezole, mianserin, mirtazapine, clonidine, guanfacine, guanabenz, guanethidine, xylazine, tizanidine, tedetomidine, methyldopa, fadolmidine, dexmedetomidine)\n* For subjects taking any drugs that might interfere with dopamine transporter SPECT imaging (neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative) must be willing and able from a medical standpoint to hold the medication for at least 5 half-lives prior to screening DaTSCANä imaging.\n\nExclusion criteria\n\n* Subjects lacking capacity according to investigator's judgment;\n* Subjects with a clinical diagnosis of dementia as determined by the investigator;\n* Subjects with current or a recent history of drug or alcohol abuse\u002Fdependence;\n* Current treatment with anticoagulants (e.g. warfarin, heparin) that might preclude the arterial cannulation and the safe completion of the lumbar puncture.\n* Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.\n* Negative Allen test in both hands,\n* Use of any of the following drugs that might interfere with dopamine transporter SPECT imaging: neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative, within 5 months of Screening.\n* Use of any medications with known actions on I2BS (e.g. idaxozan, efaroxan, yohimbine, atomoxetine, atipamezole, mianserin, mirtazapine, clonidine, guanfacine, guanabenz, guanethidine, xylazine, tizanidine, tedetomidine, methyldopa, fadolmidine, dexmedetomidine);\n* Use of investigational drugs or devices within 60 days prior to Baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10).\n* History of cancer within the last 5 years, with the exception of non-metastatic basal cell carcinoma of the skin.\n* Subjects with current or recent history of drug or alcohol abuse\u002Fdependence.\n* Contraindication to MRI, such as presence of metal devises or implants (e.g. pacemaker, vascular- or heart- valves, stents, clips), metal deposited in the body (e.g. bullets or shells), or metal grains in the eyes;\n* Claustrophobia or history of back pain that makes prolonged laying on the PET, SPECT, or MRI scanner intolerable.\n* Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).\n* Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgment of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results;\n* History of suicidal behavior or active suicidal ideation;\n* Pregnancy or breastfeeding or intent to become pregnant in the next 18 months;",{"count":174,"type":20},44,"In this study, the researchers aim to find a biomarker of PD. Using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The PET and SPECT scans use small amounts of radiation and specific compounds called tracers, to study chemical changes in the brain in a way not possible with any other procedure. The MRI uses magnetic fields to generate images of brain structure and function",[152,151,153,154,155,26],{"date":158,"type":31},{"date":179,"type":31},"2021-11-01",{"date":162,"type":20},{"name":164,"class":38},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":77,"sex":113,"minAge":17,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":21,"phases":192,"briefSummary":194,"conditions":195,"keywords":204,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":39},"100596956","phase-3-psma-pet-combined-with-mri-for-the-detection-of-pca-100596956","NCT07052214","PSMA PET Combined With MRI for the Detection of PCa","A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).","BiPASS","Inclusion Criteria:\n\n1. Male, at least 18 years old.\n2. Have a clinical suspicion of PCa, and will undergo template biopsy, based on either: an initial MRI examination (PI-RADS 3-4) within 3 months (92 days) before enrollment, or no MRI evidence (PI-RADs 1-2) within 3 months (92 days) before enrollment, but a clinician indicated intent to proceed with template biopsy due to non-imaging risk factors.\n\nThese are non-imaging risk factors that would lead a patient to be considered for a template biopsy (including but not exclusive to):\n\n1. Persistently elevated or rising PSA i. PSA ≥ 3.0 ng\u002FmL ii. Rising PSA velocity (e.g., \\>0.35-0.75 ng\u002FmL\u002Fyear over 2-3 years) is also considered suspicious, especially in men with PSA\\\u003C10ng\u002FmL.\n2. High PSA density (PSAD) i. PSA density \\> 0.15 ng\u002FmL\u002Fcm³ is considered high-risk for csPCa. ii. Calculated as PSA (ng\u002FmL) divided by prostate volume (from MRI).\n3. Abnormal digital rectal examination (DRE) i. abnormal findings include:\n\n   1. Nodules\n   2. Induration\n   3. Asymmetry\n   4. Fixation of the prostate ii. An abnormal DRE in any PSA range (including \\\u003C3 ng\u002FmL) increases cancer suspicion.\n\nb) Strong family history of prostate cancer: i. First-degree relative (father or brother) with PCa ii. Any relative diagnosed at \\\u003C65 years of age iii. Multiple affected relatives iv. Known hereditary cancer syndromes (e.g., BReast CAncer gene \\[BRCA\\]1\u002F2, Homeobox protein Hox-B13 \\[HOXB13\\] mutations) c) Other high-risk biomarkers i. 4Kscore: ≥ 7.5-10% risk of high-grade PCa ii. PHI (Prostate Health Index): ≥ 35 suggests elevated risk iii. Prostate Cancer Antigen 3 (PCA3) Score: ≥ 35 considered positive and associated with increased risk of PCa.\n\niv. Any other established biomarker with values in the high-risk range d) Clinical presentation i. Symptoms suggestive of locally advanced disease (e.g., urinary obstruction, bone pain) ii. Prior negative MRI with ongoing clinical concern 3. Prostate biopsy naïve participants. 4. Eastern Cooperative Oncology Group performance status (ECOG PS) ≤2 per FDA guidelines. 5. Have the capacity to understand the study and be able and willing to comply with all protocol requirements. 6. Provides consent for anatomical template with\u002Fwithout targeted biopsy based on clinical risk, MRI and PSMA PET result. 7. Participants must comply with the radiation protection rules (including hospital admissions and isolation) that are used by the treating institution to protect their contacts and the general public, especially if a female partner of the participant is or could be pregnant.\n\n8\\. Must agree to practice adequate precautions to prevent pregnancy in a female partner and to avoid potential problems associated with radiation exposure to the unborn child (Recommendations related to contraception and pregnancy testing in clinical trials Version 1.1, (CTFG \\[Clinical Trial Facilitation Group\\], 2020). Details of contraceptive measures to be taken by male participants and their female partners are described in Appendix 4 of the Protocol.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Has had prior treatment for PCa or prior diagnosis of csPCa.\n2. Obvious metastatic disease on prior conventional imaging.\n3. Previous diagnosis of cancer of any primary origin (excluding basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy).\n4. Active prostate infection, or urinary test results suggestive of an active urinary tract infection, evident on medical history, within 4 weeks of enrollment.\n5. Prior pelvic irradiation\n6. Demonstrate radiographic findings of PI-RADS 5.\n7. Has abnormalities in physical examination and protocol-specified clinical laboratory tests during the Screening Period that, in the judgment of the investigator, could affect safety or compliance; and\u002For is deemed not suitable for participating in this trial in the opinion of the investigator.\n8. Unable to understand or is unwilling to sign a written informed consent document or to follow investigational procedures in the opinion of the investigator.\n9. Is unable to attain or remain in a supine position while a PET\u002FCT scan is being performed or unable to tolerate a PET\u002FCT scan\n10. Unable or unwilling to undergo clinical prostate biopsy, has known allergies, hypersensitivity, or intolerance to the investigational drug\u002Fcomparator or its excipients.\n11. Have prior use of radionuclides with an interval of less than 10 effective half-lives before the administration of 68Ga-PSMA-11.\n12. Is participating or plans to participate in any experimental drug or device trial during the study period that are considered outside of therapeutic SOC. Studies involving modifications of sequencing or timing of therapeutic regimens\u002Finterventions would be deemed eligible to enroll",{"count":191,"type":20},204,[193],"PHASE3","This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).",[196,197,198,199,200,201,26,202,203],"PCA","Prostate Cancer","Prostatic Neoplasm","PSMA PET","Diagnostic Imaging","Elevated PSA","Prostate Biopsy","Carcinoma of the Prostate",[205,206,207,208,209,210,211,212],"Molecular Imaging","Biopsy Naive","Magnetic Resonance Imaging","Biopsy","Targeted Biopsy","Radiopharmaceuticals","Cancer Detection","Urologic Oncology","2025-09-03",{"date":215,"type":31},"2025-09-10",{"date":217,"type":31},"2025-08-18",{"date":219,"type":20},"2026-11",{"name":221,"class":222},"Telix Pharmaceuticals (Innovations) Pty Limited","INDUSTRY",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":229,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":230,"conditions":231,"keywords":235,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":68},"100569186","prostate-specific-membrane-antigen-petct-imaging-in-psma-related-disease-patients-100569186","NCT06690970","Prostate Specific Membrane Antigen PET\u002FCT Imaging in PSMA-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":48,"type":20},"To evaluate the potential usefulness of 68Ga\u002F18F-PSMA\u002FPSFA positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.",[232,197,26,233,234],"PSMA-related Disease","Metastasis","FAP",[57,236,234],"PSMA","2025-08-07",{"date":239,"type":31},"2025-08-11",{"date":241,"type":31},"2020-09-01",{"date":243,"type":20},"2027-12-01",{"name":67,"class":38},{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":39},"100506391","68ga-fapi-lm3-petct-imaging-in-patients-with-fapsstr2-positive-disease-and-compared-with-18f-fdg-100506391","NCT05873777","68Ga-FAPI-LM3 PET\u002FCT Imaging in Patients With FAP\u002FSSTR2 Positive Disease and Compared With 18F-FDG","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order);\n* (ii) patients with suspected or newly diagnosed or previously malignant disease, with either FAP or SSTR2 positive expression (supporting evidence may include MRI, CT, and pathology report etc);\n* (iii) patients who had scheduled both 18F-FDG and 68Ga-FAPI-LM3 PET\u002FCT scans;\n* (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant disease;\n* (ii) patients with pregnancy;\n* (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":252,"type":20},30,[117],"As a new dual receptor (SSTR2 and FAP) targeting PET radiotracer, 68Ga-FAPI-LM3 is promising as an excellent imaging agent applicable to SSTR2 positive diseases. In this research, we investigate the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-LM3 in healthy volunteers. Moreover, we evaluate the potential usefulness of 68Ga-FAPI-LM3 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of lesions in SSTR2 positive diseases, and compared with 18F-FDG PET\u002FCT.",[256,234,122],"SSTR2",[256,234,122],"2025-08-05",{"date":260,"type":31},"2025-08-08",{"date":262,"type":31},"2023-04-09",{"date":264,"type":20},"2025-12-31",{"name":266,"class":38},"The First Affiliated Hospital of Xiamen University",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":146,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":39},"100600523","phase-2-pancreatic-cancer-diagnosis-with-fapi-pet-imaging-100600523","NCT07098598","Pancreatic Cancer Diagnosis With FAPI-PET Imaging","Diagnostic Efficacy of 18F-FAPI-74 PET\u002FCT in Patients With Pancreatic Cancer","Inclusion Criteria:\n\n* Suspected primary or recurrent pancreatic cancer\n* Subjects must be male or female aged 18-85 years.\n* WHO performance score 0-2.\n* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.\n\nExclusion Criteria:\n\n* Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included.\n* Study subject is not able to understand the purpose of the study.\n* Medical conditions prohibiting whole-body PET\u002FCT imaging.",{"count":275,"type":20},100,[277,193],"PHASE2","Staging pancreatic cancer (PC) presents a clinical challenge. Triphasic whole body CT is the primary imaging method in diagnosing, staging and during follow up. Conventional PET\u002FCT with 18F-labelled fluorodeoxyglucose (18F-FDG) has its limitations and therefore has a secondary role in imaging pancreatic cancer patients. These conventional imaging methods are good in detecting primary tumors and distant metastasis but poor in detecting local lymph node metastasis. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targets FAP, a protein overexpressed in cancer-associated fibroblasts. It presents a potential new PET imagining tool.\n\nThe objective of this prospective diagnostic study is to evaluate the diagnostic efficacy of 18F-FAPI-74 PET\u002FCT in patients with PC. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with PC in primary staging and when suspected recurrence. 100 patients with PC are enrolled on whom PET\u002FCT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.",[26,280,281,282,283,284,285,286],"Pancreatic Cancer","FAPI","Diagnostics","Recurrent Pancreatic Cancer","Oncologic Surgery","Imaging, Diagnostic","Staging","2025-07-31",{"date":289,"type":31},"2025-08-01",{"date":291,"type":31},"2024-10-09",{"date":293,"type":20},"2026-10",{"name":295,"class":296},"Turku University Hospital","OTHER_GOV",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":77,"sex":16,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":39},"100579698","establishment-of-the-chinese-preclinical-alzheimers-disease-study-with-multiple-neuroimaging-100579698","NCT06827678","Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging","Inclusion Criteria:\n\n1. Cognitive unimpaired(CU) controls:\n\n(1) Aged between 45 and 90 years; no gender restrictions； (2) Cognitive function is assessed as normal by the researcher based on cognitive tests, with a Clinical Dementia Rating (CDR) score of 0; (3) Confirmed by the researcher to have no neurological diseases, major chronic illnesses, malignant tumors, or acute infectious diseases; (4) No family history of Alzheimer's disease (AD) or other neurological diseases related to cognitive impairment and movement disorders; (5) Able to understand and provide written informed consent before any assessment; (6) Female subjects must provide medical documentation proving they have undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) or have been menopausal for over one year. If they are still of childbearing potential, they must use effective contraceptive measures during the study; (7) Male subjects must use effective contraceptive measures during the study period and are prohibited from donating sperm during this time; (8) Willing and able to comply with all study procedures. 2. Cognitive impaired(CI) patients:\n\n1. Aged between 45 and 90 years; no gender restrictions;\n2. CDR score ≥ 0.5;\n3. MMSE score ≤ 24;\n4. Brain MRI findings support the diagnosis of AD, with no evidence of other neurological diseases;\n5. Any medications taken to alleviate AD symptoms must be maintained at a stable dose for at least 30 days before study participation;\n6. Written informed consent must be provided by the subject or their legal guardian\u002Fcaregiver;\n7. If necessary, subjects may be accompanied by a caregiver;\n8. Before any assessment, the subject or their legal representative must understand and sign a written informed consent form;\n9. Female subjects must provide medical documentation confirming surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation).\n\nExclusion Criteria:\n\n* All subjects:\n\n  1. Presence of severe neurological diseases or serious disorders affecting the gastrointestinal, cardiovascular, hepatic, renal, hematologic, oncologic, endocrine, respiratory, or immune systems;\n  2. Presence of MRI-incompatible metal implants, including cardiac pacemakers, intravascular metal devices, insulin pumps, cochlear implants, nerve stimulators, or cerebral aneurysm clips;\n  3. Inability to tolerate MRI noise or a history of claustrophobia;\n  4. Exposure to ionizing radiation exceeding 50 mSv within the past year due to participation in other clinical or scientific research;\n  5. History of drug or alcohol abuse;\n  6. Pregnancy or lactation;\n  7. Poor venous access, making repeated venipuncture infeasible;\n  8. Use of experimental drugs or devices with unknown efficacy or safety within the past month;\n  9. Allergy to any components of the tracer injection;\n  10. Any condition that, in the investigator's judgment, may pose a risk or compromise the integrity of the study.","45 Years","90 Years",{"count":306,"type":20},3000,"The goal of this observational study is to investigate neuroimage and biomarkers in the Alzheimer's continuum in Chinese population. We aimed to:\n\n* To reveal the progress of AD by multiple neuroimage and biomarkers;\n* To reveal the longitudinal change of biomarkers and cognition of AD in Chinese population;\n* To investigate the interaction of markers between body and brain;\n* To set up new markers by neuroimage.",[309,26],"Alzheimer Disease",[311,312,313,314],"Alzheimer's Disease","PET imaging","Biomarker","Body Imaging","2025-06-02",{"date":317,"type":31},"2025-06-05",{"date":319,"type":31},"2022-08-01",{"date":321,"type":20},"2027-07-30",{"name":323,"class":38},"Huashan Hospital",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":21,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":39},"100548312","early-phase-1-68gaga-sa-dabi-4-pet-imaging-of-stimulator-of-interferon-gene-expression-in-cancer-patients-100548312","NCT06419361","[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients","Inclusion Criteria:\n\n1. At least 18 years of age.\n2. Signed informed consent.\n3. Patients with suspected or newly diagnosed or previously malignant disease.\n\nExclusion Criteria:\n\n1. Patients with non-malignant disease.\n2. Patients with pregnancy.\n3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.\n4. Known or expected hypersensitivity to \\[68Ga\\]Ga-Sa-DABI-4 or any of its components.\n5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.",{"count":252,"type":20},[23],"Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist (\\[68Ga\\]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.",[334,335,26],"Stimulator of Interferon Gene","Cancer","2025-05-29",{"date":338,"type":31},"2025-06-04",{"date":340,"type":31},"2024-05-30",{"date":342,"type":20},"2026-12-31",{"name":344,"class":38},"First Affiliated Hospital of Chongqing Medical University",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":21,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":359,"locationsCount":39},"100545858","early-phase-1-68ga-psfa-pet-imaging-in-patients-with-psmafap-positive-disease-100545858","NCT06387381","68Ga-PSFA PET Imaging in Patients With PSMA\u002FFAP Positive Disease","Inclusion Criteria:\n\n1. At least 18 years of age.\n2. Signed informed consent.\n3. Patients with suspected or newly diagnosed or previously malignant disease, with either PSMA or FAP positive expression (supporting evidence may include MRI, CT, and pathology report, etc).\n\nExclusion Criteria:\n\n1. Patients with non-malignant disease.\n2. Patients with pregnancy.\n3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.\n4. Known or expected hypersensitivity to 68Ga-PSFA or any of its components.\n5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.",{"count":252,"type":20},[23],"As a new dual receptor (PSMA and FAP) targeting PET radiotracer, 68Ga-PSFA is promising as an excellent imaging agent applicable to PSMA\u002FFAP positive diseases. In this research, we investigate the safety, biodistribution and potential usefulness of 68Ga-PSFA positron emission tomography (PET) for the diagnosis of lesions in PSMA\u002FFAP positive diseases.",[236,234,122],{"date":338,"type":31},{"date":357,"type":31},"2024-05-20",{"date":342,"type":20},{"name":344,"class":38},{"id":361,"slug":362,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":366,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":367,"conditions":368,"keywords":372,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":39},"100571856","glucagon-like-peptide-1-receptor-petct-in-glp-1r-related-disease-100571856","NCT06725693","Glucagon-like Peptide-1 Receptor PET\u002FCT in GLP-1R Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":48,"type":20},"To evaluate the potential usefulness of 68Ga\u002F18F-Exendin 4 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.",[369,370,371,26],"GLP1-R-related Disease","Tumor","Insulinoma",[57,373],"GLP1-R","2025-02-07",{"date":376,"type":31},"2025-02-11",{"date":378,"type":31},"2019-02-01",{"date":380,"type":20},"2027-11-01",{"name":67,"class":38},{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":388,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":398,"leadSponsor":400,"locationsCount":39},"100569185","somatostatin-receptor-petct-in-sstr-related-disease-patients-100569185","NCT06690957","Somatostatin Receptor PET\u002FCT in SSTR-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled SSTR PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":48,"type":20},"To evaluate the potential usefulness of 68Ga\u002F18F-TATE\u002FJR11\u002FLM3 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.",[391,370,26,233],"SSTR-related Disease",[57,393,394,395],"SSTR","Angonist","Antagonist",{"date":376,"type":31},{"date":378,"type":31},{"date":399,"type":20},"2027-10-01",{"name":67,"class":38},{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":407,"targetDuration":4,"studyType":21,"phases":409,"briefSummary":410,"conditions":411,"keywords":413,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":421,"locationsCount":39},"100569168","chemokine-receptor-4-petct-imaging-of-cxcr4-related-diseases-100569168","NCT06690736","Chemokine Receptor 4 PET\u002FCT Imaging of CXCR4-Related Diseases","Inclusion Criteria:\n\n* suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients\n* 18F-FDG PET\u002FCT within two weeks\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy\n* breastfeeding\n* known allergy against Pentixafor",{"count":408,"type":20},200,[117],"To evaluate the potential usefulness of 68Ga\u002F18F-Pentixafor\u002FPentixather positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.",[412,370,26,233],"CXCR4-related Disease",[57,414,415,416],"Chemokine receptor 4","Pentixafor","Pentixather",{"date":376,"type":31},{"date":419,"type":31},"2022-03-01",{"date":399,"type":20},{"name":67,"class":38},{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":428,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":435,"leadSponsor":436,"locationsCount":39},"100568963","fapi-petct-in-various-fap-related-disease-patients-100568963","NCT06688071","FAPI PET\u002FCT in Various FAP-Related Disease Patients","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled FAPI PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":48,"type":20},"To evaluate the potential usefulness of 68Ga\u002F18F-FAPI positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various FAP-related disease patients.",[431,370,26,233],"FAP-related Disease",[57,234,281],{"date":376,"type":31},{"date":419,"type":31},{"date":399,"type":20},{"name":67,"class":38},{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":77,"sex":16,"minAge":444,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":21,"phases":446,"briefSummary":447,"conditions":448,"keywords":454,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":39},"100517471","the-role-of-imaging-in-the-diagnosis-management-and-prognosis-of-possible-non-convulsive-status-epilepticus-100517471","NCT06017973","The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus","The Role of Cerebral Functional, Structural and Spectral Imaging in the Diagnosis, Management and Prognosis of Status Epilepticus: a Prospective Study in Patients with the Ictal-interictal Continuum","Inclusion Criteria:\n\n\\- The patient has possible non-convulsive status epilepticus with scalp or invasive EEG with ictal-interictal continuum patterns on EEG\n\nExclusion Criteria:\n\n* The patient has a contra-indication for MRI such as metal implants\n* The patient has contrast sensitivity\n* The patiensuffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures","16 Years",{"count":408,"type":20},[117],"The investigators propose a prospective study of 20 control subjects and 180 consecutive patients with possible non-convulsive status epilepticus (NCSE). The investigators will obtain three functional images of the brain:\n\n1. Fluorodeoxyglucose positron emission tomography (FDG-PET)\n2. Perfusion (and structural) magnetic resonance (MR) images\n3. Computed tomography (CT) perfusion.\n\nBrain hypermetabolism\u002Fhyperperfusion is a strong argument to confirm a diagnosis of non-convulsive status epilepticus.\n\nThe aim is to determine which of the three functional imaging techniques is the most sensitive and easy to obtain in the detection of hypermetabolism\u002Fhyperperfusion. The investigators will determine which EEG patterns are associated with hypermetabolism\u002Fperfusion.\n\nThe investigators will further study and describe the management with antiseizure medication and outcome of the group with possible non-convulsive status epilepticus WITH hypermetabolism\u002Fhyperperfusion versus the group with possible non-convulsive status epilpticus WITHOUT hypermetabolism\u002Fhyperperfusion.\n\nThe investigators will make recommendations for an imaging protocol in possible NCSE for widespread use. The aim is to offer guidelines to incorporate imaging in the diagnosis, management and prognosis of NCSE in patients with the ictal-interictal continuum.",[449,450,451,452,453],"Status Epilepticus","Ictal-interictal Continuum","Positron-emission Tomography","Perfusion Weighted MRI","Perfusion CT",[455,456,457,458,459,460],"possible non-convulsive status epilepticus","ictal-interictal continuum","EEG","MRI","FDG-PET","CT perfusion","2024-12-23",{"date":463,"type":31},"2024-12-27",{"date":465,"type":31},"2023-10-01",{"date":467,"type":20},"2027-09-30",{"name":469,"class":38},"Universitaire Ziekenhuizen KU Leuven",{"id":471,"slug":472,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":479,"conditions":480,"keywords":493,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":504,"locationsCount":39},"100486132","gene-expression-profiles-in-spinal-tuberculosis-100486132","NCT05610098","Gene Expression Profiles in Spinal Tuberculosis.","Comparing Gene Expression Profiles of Adults With Isolated Spinal TB to Disseminated Spinal TB Identified by 18FDG-PET\u002FCT at Time of Diagnosis, 6-and 12-months Follow-up","SpinalTBX","Inclusion Criteria\n\n1. Participant has completed the written informed consent process prior to undergoing any clinical evaluations and willing to undergo HIV testing\n2. TB spine based on clinical and radiological criteria\n3. Age 18 or older with a body weight of at least 40 kg body weight\n4. Able and willing to return to follow-up\n5. Willing to have samples, including DNA including RNA extraction, stored\n6. Willing to consistently practice a highly reliable method of pregnancy prevention\n\nExclusion Criteria\n\n1. Pregnancy or active desire to become pregnant within the next 6 months.\n2. Uncontrolled diabetes (HbA1c ≥ 6.5% \u002F random glucose concentration ≥11.1 mmol\u002Fl, fasting plasma glucose ≥ 7.0 mmol\u002Fl)\n3. Alcohol and substance abuse which might interfere with medication adherence during the trial\n4. Positive SARS-CoV-2 PCR in the past 4 weeks\n5. Suspicion of malignancy on MRI or known malignancy\n6. Suspicion of inflammatory disease and other rheumatological conditions\n7. Any person for whom the physician feels this study is not appropriate",{"count":275,"type":20},"Tuberculosis (TB) is one of the top ten causes of death worldwide with approximately 10 million cases globally and 1.2 million deaths. Sub-Saharan Africa carries the highest burden of TB. South Africa has one of the highest HIV and TB rates worldwide with an HIV prevalence rate in adults of 19% and a TB case notification rate of 615\u002F100,000 in 2019. Over many years, focus has been paid to pulmonary TB and extrapulmonary TB (EPTB) has received only little attention even though it accounts for almost a quatre of all TB cases. The diagnosis of EPTB remains challenging simply because sample collection requires invasive procedures in the absence of a blood-based diagnostic test. Spinal TB (spondylitis or spondylodiscitis caused by Mycobacterium tuberculosis) - often known as Pott's disease - accounts for up to 10% of EPTB and affects young children, people with HIV-coinfection and elderly, and often leads to lifelong debilitating disease due to devastating deformation of the spine and compression of neural structures. Little is known with regards to the extent of disease and isolated TB spine as well as a disseminated form of TB spine have been described. The latter presents with a spinal manifestation plus disseminations to other organs such as the lungs, pleura, lymph nodes, the GIT or urinary tract or even the brain.\n\nIn the Spinal TB X cohort, the investigators aim to describe the clinical phenotype of spinal TB using whole body PET\u002FCT and identify a specific gene expression profile for the different stages of dissemination and compare findings to previously described signatures for latent and active pulmonary TB. A blood-based test for spinal TB would lead to earlier diagnosis and treatment in all settings globally and improve treatment outcome of this devastating disease.",[481,482,483,484,485,486,487,488,489,490,491,122,200,492],"Tuberculosis, Spinal","Tuberculosis, Osteoarticular","Tuberculosis","Mycobacterium Infections","Infections","Bone Diseases, Infectious","Musculoskeletal Diseases","Spinal Disease","Spondylitis","Spondylitis; Tuberculosis (Manifestation)","Spondylodiscitis","Diagnostic Techniques and Procedures",[494,495,496,497],"Spinal TB","tuberculous spondylodiscitis","FDG-PET\u002FCT","POC","2024-08-22",{"date":500,"type":31},"2024-08-23",{"date":502,"type":31},"2022-10-25",{"date":342,"type":20},{"name":505,"class":38},"University of Cape Town",{"id":507,"slug":508,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":517,"conditions":518,"keywords":521,"overallStatus":527,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":39},"100558994","diagnostic-performance-of-18-fdg-pet-ct-scores-for-the-diagnosis-of-polymyalgia-rheumatica-100558994","NCT06558357","Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica","Evaluation of the Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica and Comparison With Others Inflammatory Rheumatic Diseases.","RHUMATEP","Inclusion Criteria:\n\n* Having 18-FDG PET-CT between 2012 and 2024\n* Diagnosis of inflammatory rheumatism by specialist doctor\n* Adult without opposition to use there data for research\n* Affiliate to social security system\n\nExclusion Criteria:\n\n* Refusal participation\n* Patient under juridic protection","110 Years",{"count":516,"type":20},210,"Study of the diagnostic performance of 18-FDG PET scores in Polymyalgia rheumatica and comparaison with others inflammatories diseases.",[519,520,451],"Inflammatory Rheumatism","18-FDG",[522,523,524,525,526],"Polymyalgia rheumatica","FDG","PET","Diagnostic performance","score","NOT_YET_RECRUITING","2024-08-19",{"date":530,"type":31},"2024-08-20",{"date":532,"type":20},"2024-09-01",{"date":534,"type":20},"2024-12-31",{"name":536,"class":38},"University Hospital, Brest",{"id":538,"slug":539,"hasResults":11,"nctId":540,"briefTitle":541,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":543,"enrollmentInfo":544,"targetDuration":4,"studyType":21,"phases":546,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":39},"100531728","clinical-study-of-trop-2-petct-for-noninvasive-diagnosis-of-solid-tumors-100531728","NCT06203574","Clinical Study of TROP-2 PET\u002FCT for Noninvasive Diagnosis of Solid Tumors","Inclusion Criteria:\n\n1. Be between 18 and 65 years of age and of either sex.\n2. Patients with colorectal cancer confirmed by puncture or surgical pathology.\n3. Written informed consent signed by the subject or legal guardian or caregiver.\n4. Willingness and ability to cooperate with all programs of this study.\n\nExclusion Criteria:\n\n1. Severe hepatic or renal insufficiency;\n2. Targeted therapy before radiotherapy or PET\u002FCT scan；\n3. Renal function: serum creatinine less than or equal to the upper limit of the normal range;Liver function: bilirubin, AST(SGOT)\u002FALT(SGPT) less than or equal to the upper limit of the normal range；\n4. History of serious surgery in the last month. Those who have participated in other clinical trials during the same period.","65 Years",{"count":545,"type":20},60,[117],"This study will investigate the safety and preliminary diagnostic efficacy of \\[68Ga\\]Ga-NOTA-T4 or \\[18F\\]AlF-RESCA-T4 in pancreatic cancer, breast cancer, head and neck cancer, lung cancers and other types of solid tumors. Then, this study will provide a new method for the noninvasive target-specific diagnosis of pancreatic cancer, breast cancer, head and neck cancer, lung cancers and other types of solid tumors. PET imaging of TROP-2 will be integrated to TROP-2-targeted therapies in some of the included patients. Therefore, PET imaging with \\[68Ga\\]Ga-NOTA-T4 or \\[18F\\]AlF-RESCA-T4 will help select patients for targeted therapy and monitor treatment responses after the treatment.",[122,549],"Neoplasms","2024-06-14",{"date":552,"type":31},"2024-06-18",{"date":554,"type":31},"2023-12-01",{"date":556,"type":20},"2024-12-01",{"name":323,"class":38},{"id":559,"slug":560,"hasResults":11,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":304,"enrollmentInfo":564,"targetDuration":4,"studyType":21,"phases":565,"briefSummary":566,"conditions":567,"keywords":569,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":39},"100394446","comparison-of-fdg-and-fapi-in-patients-with-various-types-of-cancer-100394446","NCT04416165","Comparison of FDG and FAPI in Patients With Various Types of Cancer","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report); (iii) patients who had scheduled both 18F-FDG and 68Ga-DOTA-FAPI-04 PET\u002FCT scans; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":306,"type":20},[117],"To evaluate the potential usefulness of 68Ga-DOTA-FAPI-04 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET\u002FCT.",[568,122,233],"Tumor, Solid",[122,568,570,233],"Diagnosis","2023-08-06",{"date":573,"type":31},"2023-08-08",{"date":575,"type":31},"2019-10-20",{"date":577,"type":20},"2027-12-30",{"name":266,"class":38}]